---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-106591"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:17:22.626921+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Palvella announces QTORIN pitavastatin for DSAP; Phase 2 trial planned H2 2026

## Summary
- New candidate targets DSAP, a rare genetic skin disease with no FDA-approved therapies.
- DSAP affects an estimated >50,000 diagnosed U.S. patients and is premalignant.
- Company plans to meet FDA in H1 2026; Phase 2 trial initiation expected H2 2026.
- QTORIN pitavastatin designed to inhibit the mevalonate pathway, the causal driver of DSAP.

## SEC filing metadata
- accession: 0001104659-25-106591
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000110465925106591/0001104659-25-106591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000110465925106591/tm2530285d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-106591
- JSON: https://secwatch.observer/filing/0001104659-25-106591.json
- Plain text: https://secwatch.observer/filing/0001104659-25-106591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.